Jacobs Bruce N.'s Form 4 filing
Kymera Therapeutics, Inc. (KYMR) · filed Sep 3, 2021
- Accession no.
- 0000899243-21-035158
- Filed
- Sep 3, 2021
- Trade date
- Sep 3, 2021
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $601.2K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Jacobs Bruce N.CIK 0001821074 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 3, 2021 | Common Stock | MOption exerciseDisposed | −10,000 | $2.08 | −$20,800 | 17,256 | Direct | |
| Sep 3, 2021 | Common Stock | SSaleDisposed | −8,500 | $60.05F2 | −$510,425 | 8,756 | Direct | |
| Sep 3, 2021 | Common Stock | SSaleDisposed | −1,500 | $60.50F3 | −$90,750 | 7,256 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 3, 2021 | Common Stock | AGrant or awardDisposed | −10,000 | $0.00 | $0 | 209,899 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $59.41 to $60.35. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.42 to $60.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.